Search Results
10 protocol(s) meet the specified criteria
102833Open  
Randomized Phase III Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Compared with CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

103123Open  
Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

103695Not Open *
Pilot Trial Evaluating the Combination of Reolysin and Carfilzomib in Multiple Myeloma

107029Open  
Two-Part Phase I/II Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

109376Open  
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous Transplantation in SubjectS with Multiple Myeloma - GENESIS Study

112055Open  
Phase IB Study of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

112480Open  
Phase II, Open-Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma who had Three or More Prior Lines of Treatment, are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent, and have Failed an Anti-CD38 Antibody (DREAMM 2)

87890Open  
Phase I Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies

98381Open  
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

99122Open  
Phase II, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement